Tirzepatide-Induced Injection Site Reaction

A male in his 70s developed a rash on his lower abdomen after changing his subcutaneous injection drug from dulaglutide to tirzepatide. The rash diminished after stopping tirzepatide injection. This case illustrated that tirzepatide can potentially lead to an injection site rash, despite another glu...

Descripción completa

Detalles Bibliográficos
Autor principal: Mizumoto, Junki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10575762/
https://www.ncbi.nlm.nih.gov/pubmed/37842452
http://dx.doi.org/10.7759/cureus.45181
_version_ 1785120979266043904
author Mizumoto, Junki
author_facet Mizumoto, Junki
author_sort Mizumoto, Junki
collection PubMed
description A male in his 70s developed a rash on his lower abdomen after changing his subcutaneous injection drug from dulaglutide to tirzepatide. The rash diminished after stopping tirzepatide injection. This case illustrated that tirzepatide can potentially lead to an injection site rash, despite another glucagon-like peptide-1 (GLP-1) receptor agonist (RA) being used without adverse reactions. Injection site reactions are one of the potential adverse events associated with GLP-1 RA use. To the best of our knowledge, this is the first reported case of tirzepatide-induced injection site reaction.
format Online
Article
Text
id pubmed-10575762
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-105757622023-10-15 Tirzepatide-Induced Injection Site Reaction Mizumoto, Junki Cureus Dermatology A male in his 70s developed a rash on his lower abdomen after changing his subcutaneous injection drug from dulaglutide to tirzepatide. The rash diminished after stopping tirzepatide injection. This case illustrated that tirzepatide can potentially lead to an injection site rash, despite another glucagon-like peptide-1 (GLP-1) receptor agonist (RA) being used without adverse reactions. Injection site reactions are one of the potential adverse events associated with GLP-1 RA use. To the best of our knowledge, this is the first reported case of tirzepatide-induced injection site reaction. Cureus 2023-09-13 /pmc/articles/PMC10575762/ /pubmed/37842452 http://dx.doi.org/10.7759/cureus.45181 Text en Copyright © 2023, Mizumoto et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Dermatology
Mizumoto, Junki
Tirzepatide-Induced Injection Site Reaction
title Tirzepatide-Induced Injection Site Reaction
title_full Tirzepatide-Induced Injection Site Reaction
title_fullStr Tirzepatide-Induced Injection Site Reaction
title_full_unstemmed Tirzepatide-Induced Injection Site Reaction
title_short Tirzepatide-Induced Injection Site Reaction
title_sort tirzepatide-induced injection site reaction
topic Dermatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10575762/
https://www.ncbi.nlm.nih.gov/pubmed/37842452
http://dx.doi.org/10.7759/cureus.45181
work_keys_str_mv AT mizumotojunki tirzepatideinducedinjectionsitereaction

Ejemplares similares